Cidara Therapeutics, Inc. focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in June 2014. The company was founded in 2012 and is based in San Diego, California.
Cidara Therapeutics (CDTX): Q2 GAAP EPS of -$0.45 misses by $0.14.Revenue of $3.4M misses by $0.83M.Cash and equivalents and restricted cash totaled $64.1M as of June 30, 2020 vs. $60.3M as of December 31, 2019."We are pleased to have dosed the first patient in our Phase 3 ReSPECT trial, which is evaluating rezafungin for...
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find articles about an individual hedge fund's trades on numerous financial […]
Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that it has been added to the Russell 3000® Index at the conclusion of the Russell indexes annual reconstitution, effective upon the U.S. market open today, June 29, 2020. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Russell indexes are part of FTSE Russell, a leading global index provider.